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Keeping pace with emerging evidence is an ongoing
challenge to timely development of clinical practice
guidelines. In an effort to respond promptly to new
evidence, the American College of Cardiology (ACC)/
American Heart Association (AHA) Task Force on Practicetions that are affected by evolving data or opinion.
New evidence is reviewed in an ongoing manner to
respond quickly to important scientiﬁc and treat-
ment trends that could have a major impact on patient
outcomes and quality of care. Evidence is reviewed
at least twice a year, and updates are initiated on an
as-needed basis and completed as quickly as possible
while maintaining the rigorous methodology that the ACC
and AHA have developed during their partnership of >20
years.
A focused update is initiated when new data that are
deemed potentially important for patient care are pub-
lished or presented at national and international meet-
ings (Section 1.1, “Methodology and Evidence Review”).
Through a broad-based vetting process, the studies
included are identiﬁed as being important to the relevant
patient population. The focused update is not intended to
be based on a complete literature review from the date of
the previous guideline publication but rather to include
pivotal new evidence that may effect changes in current
recommendations. Speciﬁc criteria or considerations for
inclusion of new data include the following:
 Publication in a peer-reviewed journal;
 Large, randomized, placebo-controlled trial(s);
 Nonrandomized data deemed important on the basis
of results affecting current safety and efﬁcacy as-
sumptions, including observational studies and meta-
analyses;
 Strength/weakness of research methodology and
ﬁndings;
 Likelihood of additional studies inﬂuencing current
ﬁndings;
 Impact on current performance measures and/or likeli-
hood of need to develop new performance measure(s);
 Request(s) and requirement(s) for review and update
from the practice community, key stakeholders, and
other sources free of industry relationships or other
potential bias;
 Number of previous trials showing consistent results; and
 Need for consistency with a new guideline or guideline
updates or revisions.
In analyzing the data and developing recommenda-
tions and supporting text, a writing committee uses
evidence-based methodologies developed by the Task
Force (1). The Class of Recommendation (COR) is an esti-
mate of the size of the treatment effect, with consider-
ation given to risks versus beneﬁts as well as evidence
and/or agreement that a given treatment or procedure is
or is not useful/effective and in some situations may
cause harm. The Level of Evidence (LOE) is an estimate
of the certainty or precision of the treatment effect.
TABLE 1 Applying Classiﬁcation of Recommendations and Level of Evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend
themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.
*Data available from clinical trials or registries about the usefulness/efﬁcacy in different subpopulations, such as sex, age, history of diabetes mellitus, history of prior myocardial
infarction, history of heart failure, and prior aspirin use. †For comparative-effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use
of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.
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1931The writing committee reviews and ranks evidence sup-
porting each recommendation, with the weight of evi-
dence ranked as LOE A, B, or C, according to speciﬁc
deﬁnitions that are included in Table 1. Studies are iden-
tiﬁed as observational, retrospective, prospective, or
randomized as appropriate. For certain conditions for
which inadequate data are available, recommendations
are based on expert consensus and clinical experience
and are ranked as LOE C. When recommendations at
LOE C are supported by historical clinical data, appro-
priate references (including clinical reviews) are cited if
available. For issues about which sparse data areavailable, a survey of current practice among the clini-
cians on the writing committee is the basis for LOE C
recommendations, and no references are cited. The
schema for COR and LOE is summarized in Table 1, which
also provides suggested phrases for writing recommen-
dations within each COR. A new addition to this meth-
odology is separation of the Class III recommendations to
delineate whether the recommendation is determined to
be of “no beneﬁt” or is associated with “harm” to the
patient. In addition, in view of the increasing number of
comparative-effectiveness studies, comparator verbs and
suggested phrases for writing recommendations for the
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1932comparative effectiveness of one treatment or strategy
versus another have been added for COR I and IIa, LOE A
or B only.
In view of the advances in medical therapy across the
spectrum of cardiovascular diseases, the Task Force has
designated the term guideline-directed medical therapy
(GDMT) to represent medical therapy that is strongly
recommended by (primarily Class I and IIa) ACC/AHA
guidelines. The term, GDMT, will be used herein. It is
anticipated that what currently constitutes GDMT will
evolve over time as new therapies and evidence emerge.
Because the ACC/AHA practice guidelines address
patient populations (and healthcare providers) residing
in North America, drugs that are currently unavailable in
North America are discussed in the text without a spe-
ciﬁc COR. For studies performed in large numbers of
subjects outside North America, a writing committee
reviews the potential impact of different practice pat-
terns and patient populations on the treatment effect
and relevance to the ACC/AHA target population to
determine whether the ﬁndings should inform a speciﬁc
recommendation.
The ACC/AHA practice guidelines are intended to assist
healthcare providers in clinical decision making by
describing a range of generally acceptable approaches to
the diagnosis, management, and prevention of speciﬁc
diseases or conditions. The guidelines are intended to
deﬁne practices that meet the needs of most patients in
most circumstances. The ultimate judgment about care of
a particular patient must be made by the healthcare pro-
vider and patient in light of all the circumstances pre-
sented by that patient. As a result, situations may arise in
which deviations from these guidelines are appropriate.
In clinical decision making, consideration should be given
to the quality and availability of expertise in the area
where care is provided. When these guidelines are used as
the basis for regulatory or payer decisions, the goal should
be improvement in quality of care.
Prescribed courses of treatment in accordance with
these recommendations are effective only if they are fol-
lowed. Because lack of patient understanding and
adherence may adversely affect outcomes, physicians and
other healthcare providers should engage the patient’s
active participation in prescribed medical regimens and
lifestyles. In addition, patients should be informed of the
risks and beneﬁts of and alternatives to a particular
treatment and should be involved in shared decision
making whenever feasible, particularly for COR IIa and
IIb, for which the beneﬁt-to-risk ratio may be lower.
The Task Force makes every effort to avoid actual,
potential, or perceived conﬂicts of interest that may
arise as a result of industry relationships, professional
biases, or personal interests among the members of the
writing group. All writing committee members and peerreviewers of the guideline are required to disclose all
current healthcare–related relationships, including those
existing 12 months before initiation of the writing effort.
In December 2009, the ACC and AHA implemented a new
policy for relationships with industry and other entities
(RWI) that requires the writing committee chair plus a
minimum of 50% of the writing committee to have no
relevant RWI (Appendix 1 for the ACC/AHA deﬁnition of
relevance). These statements are reviewed by the Task
Force and all members during each conference call and/or
meeting of the writing committee and are updated as
changes occur. All guideline recommendations require a
conﬁdential vote by the writing committee and must be
approved by a consensus of the voting members. Mem-
bers are not permitted to draft or vote on any text or
recommendations pertaining to their RWI. Members of
this writing group, who recused themselves from voting,
are indicated, and speciﬁc section recusals are noted in
Appendix 1. Authors’ and peer reviewers’ RWI pertinent
to this guideline are disclosed in Appendices 1 and 2,
respectively. Additionally, to ensure complete trans-
parency, this writing group members’ comprehensive
disclosure information—including RWI not pertinent to
this document—is available as an online supplement.
Comprehensive disclosure information for the Task Force
is also available online. The work of this writing group
is supported exclusively by the ACC, AHA, American
Association for Thoracic Surgery (AATS), Preventive
Cardiovascular Nurses Association (PCNA), Society for
Cardiovascular Angiography and Interventions (SCAI),
and Society of Thoracic Surgeons (STS) without commer-
cial support. Writing group members volunteered their
time for this activity.
To maintain relevance at the point of care for practicing
physicians, the Task Force continues to oversee an
ongoing process improvement initiative. As a result, in
response to pilot projects, several changes to these
guidelines will be apparent, including limited narrative
text and a focus on summary and evidence tables (with
references linked to abstracts in PubMed).
In April 2011, the Institute of Medicine released 2 re-
ports: Finding What Works in Health Care: Standards for
Systematic Reviews and Clinical Practice Guidelines We
Can Trust (2,3). It is noteworthy that the ACC/AHA prac-
tice guidelines were cited as being compliant with many
of the standards that were proposed. A thorough review
of these reports and our current methodology is under
way, with further enhancements anticipated.
The recommendations in this focused update are
considered current until they are superseded in another
focused update or the full-text guideline is revised.
Guidelines are ofﬁcial policy of the ACC and AHA.
Jeffrey L. Anderson, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
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19331. INTRODUCTION
These guidelines are intended to apply to adult patients
with stable known or suspected ischemic heart disease
(IHD), including those with new-onset chest pain (i.e., low-
risk unstable angina) or stable pain syndromes. Patients
who have “ischemic equivalents,” such as dyspnea or arm
pain with exertion, are included in the latter group. Many
patients with IHD may become asymptomatic with appro-
priate therapy. Accordingly, the follow-up sections of this
guideline pertain to patients who were previously symp-
tomatic, including those who have undergone percuta-
neous coronary intervention (PCI) or coronary artery bypass
graft (CABG). In this document, “coronary angiography” is
understood to refer to invasive coronary angiography.
1.1 Methodology and Evidence Review
Late-breaking clinical trials presented at the 2012 scien-
tiﬁc meetings of the ACC, AHA, and European Society of
Cardiology, as well as other selected data reported
through October, 2013, were reviewed by the 2012 stable
ischemic heart disease (SIHD) guideline writing commit-
tee along with the Task Force and other experts to iden-
tify trials and other key data that might affect guideline
recommendations. On the basis of the criteria and con-
siderations noted previously (see Preamble), recently
published trial data and other clinical information were
considered important enough to prompt a focused update
of the 2012 SIHD guideline (4). Evidence considered for
deliberation by the writing group was added to evidence
tables in the Data Supplement available online, although
it did not result in recommendation changes. Among the
topics considered for inclusion in the focused update was
the use of fractional ﬂow reserve (FFR) for assessing in-
termediate coronary lesions, including newer data from
the FAME (Fractional Flow Reserve Versus Angiography
for Multivessel Evaluation) 2 study (5). Although this was
acknowledged to be an important new contribution to the
literature, it did not alter the recommendations for FFR
made in the 2012 full-text guideline (4).
Consult the full-text version or the executive summary
of the 2012 SIHD guideline for policy on clinical areas not
covered by the focused update (4,6). The individual rec-
ommendations in this focused update will be incorpo-
rated into future revisions or updates of the full-text
guideline.
1.2 Organization of Committee and Relationships With Industry
For this focused update, representative members of the
2012 stable ischemic heart disease (SIHD) guideline
writing committee were invited to participate, and they
were joined by additional invited members to form a new
writing group, referred to as the 2014 focused update
writing group. Members were required to disclose all RWIrelevant to the data under consideration. The writing
group included representatives from the ACC, AHA, AATS,
PCNA, SCAI, and STS.
1.3 Review and Approval
This document was reviewed by 5 ofﬁcial reviewers from
the ACC and the AHA, as well as 1 reviewer each from the
AATS, PCNA, SCAI, and STS; and 33 individual content
reviewers, including members of the American College of
Physicians, ACC Imaging Section Leadership Council, ACC
Interventional Section Leadership Council, ACC Preven-
tion of Cardiovascular Disease Section Leadership Coun-
cil, ACC Surgeons’ Council, AHA Council on Clinical
Cardiology, and the Association of International Gover-
nors. Reviewers’ RWI information was collected and
distributed to the writing group and is published in this
document (Appendix 2).
This document was approved for publication by the
governing bodies of the ACC, AHA, and by other partner
organizations, the AATS, PCNA, SCAI, and STS.2. DIAGNOSIS OF SIHD
2.3 Invasive Testing for Diagnosis of Coronary Artery Disease
in Patients With Suspected SIHD: Recommendations
(New Section)
See Online Data Supplement 1 for additional information.
CLASS I
1. Coronary angiography is useful in patients with presumed
SIHD who have unacceptable ischemic symptoms despite
GDMT and who are amenable to, and candidates for, coro-
nary revascularization. (Level of Evidence: C)
CLASS IIA
1. Coronary angiography is reasonable to deﬁne the extent and
severity of coronary artery disease (CAD) in patients with
suspected SIHD whose clinical characteristics and results of
noninvasive testing (exclusive of stress testing) indicate a
high likelihood of severe IHD and who are amenable to, and
candidates for, coronary revascularization (7–12). (Level of
Evidence: C)
2. Coronary angiography is reasonable in patients with sus-
pected symptomatic SIHD who cannot undergo diagnostic
stress testing, or have indeterminate or nondiagnostic stress
tests, when there is a high likelihood that the ﬁndings will
result in important changes to therapy. (Level of Evidence: C)
CLASS IIB
1. Coronary angiography might be considered in patients with
stress test results of acceptable quality that do not suggest
the presence of CAD when clinical suspicion of CAD remains
high and there is a high likelihood that the ﬁndings will result
in important changes to therapy. (Level of Evidence: C)
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1934This section has been added to the 2014 SIHD focused update
to ﬁll a gap in the 2012 SIHD guideline (4). It speciﬁcally
addresses the role of coronary angiography for the diagnosis
of CAD in patients with suspected SIHD.
Coronary angiography for risk stratiﬁcation has been
addressed in Section 3.3 of the 2012 SIHD full-text
guideline (4). Recommendations for use of coronary
angiography in the following speciﬁc clinical circum-
stances have been addressed in other guidelines or
statements and will not be discussed further here:
 Patients with heart failure and/or reduced ejection
fraction (13)
 Patients who have experienced sudden cardiac death
or sustained ventricular arrhythmia (14)
 Patients undergoing preoperative cardiovascular eval-
uation for noncardiac surgery (including solid organ
transplantation) (15)
 Evaluation of cardiac disease among patients who are
kidney or liver transplantation candidates (16,17)
Note that ACC/AHA guidelines for coronary angiography
were published in 1999 but not updated, and they are now
superseded by the above documents.
There are no high-quality data on which to base rec-
ommendations for performing diagnostic coronary angi-
ography because no study has randomized patients with
SIHD to either catheterization or no catheterization. Trials
in patients with SIHD comparing revascularization and
GDMT have, to date, all required angiography, most often
after stress testing, as a prerequisite for subsequent
revascularization. Additionally, the “incremental beneﬁt”
of detecting or excluding CAD by coronary angiography
remains to be determined. The ISCHEMIA (International
Study of Comparative Health Effectiveness With Medical
and Invasive Approaches) trial is currently randomizing
patients with at least moderate ischemia on stress testing
to a strategy of optimal medical therapy alone (with cor-
onary angiography reserved for failure of medical ther-
apy) or routine cardiac catheterization followed by
revascularization (when appropriate) plus optimal medi-
cal therapy. Before randomization, however, patients
with normal renal function will undergo “blinded”
computed tomography (CT) angiography to exclude them
if signiﬁcant left main CAD or no signiﬁcant CAD is pre-
sent. The writing group strongly endorses the ISCHEMIA
trial, which will provide contemporary, high-quality evi-
dence about the optimal strategy for managing patients
with nonleft main SIHD and moderate-to-severe ischemia.
In the majority of patients with suspected SIHD,
noninvasive stress testing for diagnosis and risk strati-
ﬁcation is the appropriate initial study. Importantly,
coronary angiography is appropriate only when the in-
formation derived from the procedure will signiﬁcantly
inﬂuence patient management and if the risks andbeneﬁts of the procedure have been carefully consid-
ered and understood by the patient. Coronary angiog-
raphy to assess coronary anatomy for revascularization
is appropriate only when it is determined beforehand
that the patient is amenable to, and a candidate for,
percutaneous or surgical revascularization. In patients
with abnormal, noninvasive stress testing for whom a
diagnosis of CAD remains in doubt, many clinicians
proceed to diagnostic coronary angiography. However,
in some patients, multidetector CT angiography may be
appropriate and safer than routine invasive angiog-
raphy for this purpose. Indications and contraindica-
tions to CT angiography, including subsets of patients
for whom it can be considered, are also discussed in the
2010 expert consensus document on CT angiography
(18) and the 2010 appropriate use criteria for cardiac
CT (19).
Although coronary angiography is considered the
“gold standard” for the diagnosis of CAD, it has inherent
limitations and shortcomings. Angiographic assessment
of stenosis severity relies on comparison to an adjacent,
nondiseased reference segment. In diffusely diseased
coronary arteries, lack of a normal reference segment
may lead to underestimation of lesion severity by angi-
ography. Multiple studies have documented signiﬁcant
interobserver variability in the grading of coronary artery
stenosis (20,21), with disease severity overestimated by
visual assessment when coronary stenosis is $50%
(21,22). Although quantitative coronary angiography
provides a more accurate assessment of lesion severity
than does visual assessment, it is rarely used in clinical
practice because it does not accurately assess the phys-
iological signiﬁcance of lesions (23). Many stenoses
considered to be severe by visual assessment of coronary
angiograms (i.e., $70% luminal narrowing) do not
restrict coronary blood ﬂow at rest or with maximal
dilatation, whereas others considered to be “insigniﬁ-
cant” (i.e., <70% luminal narrowing) are hemodynami-
cally signiﬁcant (24). Coronary angiography also cannot
assess whether an atherosclerotic plaque is stable or
“vulnerable” (i.e., likely to rupture and cause an acute
coronary syndrome).
Intravascular ultrasound and optical coherence to-
mography provide more precise information about the
severity of stenosis and plaque morphology than does
coronary angiography and, in certain cases, can be useful
adjunctive tests (9). These imaging procedures are dis-
cussed in the 2011 PCI guideline (9). FFR can assess the
hemodynamic signiﬁcance of angiographically “interme-
diate” or “indeterminant” lesions and allows one to
decide when PCI may be beneﬁcial or safely deferred
(24,25). It has been suggested in several studies that a PCI
strategy guided by FFR may be superior to a strategy
guided by angiography alone (5,24,26,27).
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1935Invasive procedures may cause complications. Data
from the ACC’s National Cardiovascular Data Registry
CathPCI Registry during the 2012 calendar year included a
1.5% incidence of procedural complications of diagnostic
angiography. Complications in earlier reports included
death, stroke, myocardial infarction (MI), bleeding,
infection, contrast allergic or anaphylactoid reactions,
vascular damage, contrast-induced nephropathy, ar-
rhythmias, and need for emergency revascularization
(28–32). Complications are more likely to occur in certain
patient groups, including those of advanced age
(>70 years), and those with marked functional impair-
ment (Canadian Cardiovascular Society class IV angina or
New York Heart Association class IV heart failure), severe
left ventricular dysfunction or CAD (particularly left main
disease), severe valvular disease, severe comorbid medi-
cal conditions (e.g., renal, hepatic, or pulmonary disease),
bleeding disorders, or a history of an allergic reaction to
radiographic contrast material (28–32). The risk of
contrast-induced nephropathy is increased in patients
with renal insufﬁciency or diabetes mellitus (9,33). In
deciding whether angiography should be performed in
these patients, these risks should be balanced against the
increased likelihood of ﬁnding critical CAD. The concept
of informed consent requires that risks and beneﬁts of
and alternatives to coronary angiography be explicitly
discussed with the patient before the procedure is
undertaken.
Despite these shortcomings and potential complica-
tions, coronary angiography is useful to a) ascertain the
cause of chest pain or anginal equivalent symptoms,
b) deﬁne coronary anatomy in patients with “high-risk”
noninvasive stress test ﬁndings (Section 3.3 in the 2012
full-text guideline) as a requisite for revascularization,
c) determine whether severe CAD may be the cause of
depressed left ventricular ejection fraction, d) assess for
possible ischemia-mediated ventricular arrhythmia, e)
evaluate cardiovascular risk among certain recipient and
donor candidates for solid-organ transplantation, and
f) assess the suitability for revascularization of patients
with unacceptable ischemic symptoms (i.e., symptoms
that are not controlled with medication and that limit ac-
tivity or quality of life). Coronary angiography may also be
helpful when initial stress testing is inconclusive or
yields conﬂicting results and deﬁnitive determination of
whether IHD is present will result in important changes to
therapy. The exclusion of epicardial CAD in a patient with
recurring chest pain or other potential ischemic symptoms
is particularly useful when it leads to more appropriate
treatment, including withdrawal of medications.
In a subset of patients, clinical characteristics, symp-
toms, and/or results of noninvasive testing alone indi-
cating a high likelihood of multivessel or left main
disease (e.g., large ischemic burden) may promptdiagnostic angiography and revascularization, instead of
initial stress testing. Patients with long-standing diabetes
mellitus and end-organ damage, severe peripheral
vascular disease (e.g., abdominal aortic aneurysm), or
previous chest (mantle) radiation therapy may have se-
vere CAD—particularly when ischemic symptoms are
present (28–31). Patients with a combination of typical
angina, transient heart failure, pulmonary edema, or ex-
ertional or unheralded syncope may have severe CAD.
Noninvasive testing, such as rest echocardiography
revealing multiple regional wall motion abnormalities or
electrocardiography with diffuse ischemic changes in
multiple territories, may reﬂect CAD with a large ischemic
burden and justify diagnostic angiography without prior
stress testing. The writing group has found that creating a
recommendation governing the use of angiography for
such high-risk patients remains controversial. The writing
group recognizes, however, that many clinicians believe
that prompt diagnostic angiography and revascularization,
instead of initial stress testing, are appropriate for such
high-risk patients who are likely to have underlying severe
CAD for which revascularization would confer a survival
advantage.
Coronary angiography is not routinely performed after
adequate stress testing has been negative for ischemia.
Still, stress tests can be falsely negative and, in a patient
with high pretest likelihood of CAD, Bayes’ theorem pre-
dicts that a high post-test likelihood of CAD will remain as
well. Therefore, when clinicians strongly suspect that a
stress test is falsely negative (e.g., a patient with typical
angina who also has multiple risk factors for CAD),
diagnostic angiography may be warranted. When stress
testing yields an ambiguous or indeterminate result in a
patient with a high likelihood of CAD, coronary angiog-
raphy may be preferable to another noninvasive test and
may be the most effective means to reach a diagnosis.
The frequency with which coronary angiography is
performed varies across geographic regions, and in some
areas it may be underutilized or overutilized (34). The
optimal rate of “normal” coronary angiography in clinical
practice remains undeﬁned. In the ACC’s National Cardio-
vascular Data Registry CathPCI Registry, approximately
45% of elective cardiac catheterizations performed at
hospitals did not detect clinically signiﬁcant (deﬁned as
>50% luminal diameter) stenoses (29,35), although rates
varied markedly between hospitals (i.e., range, 0% to 77%)
(35). Hospitals with lower rates of signiﬁcant CAD at cath-
eterization were more likely to have performed angiog-
raphy on younger patients; those with no symptoms or
atypical symptoms; and those with negative, equivocal, or
unperformed functional status assessment (35). Even
among those with a positive result on a noninvasive test,
only 41% of patients were found to have signiﬁcant CAD
(36). In a study performed within the Veterans Health
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1936Administration, 21% of patients undergoing elective cath-
eterization had “normal” coronary arteries (deﬁned as
having no lesions$20%). Themedian proportion of normal
coronary arteries was 10.8% among hospitals in the lowest
quartile and 30.3% among hospitals in the highest quartile
(37). The authors concluded that factors causing variation
in patient selection for coronary angiography exist in in-
tegrated non–fee-for-service health systems as well as in
fee-for-service systems.
Angiographically normal or near-normal coronary ar-
teries are more common among women, who are more
likely than men to have myocardial ischemia due to
microvascular disease. The relatively high proportion of
patients with ischemia and no signiﬁcant epicardial ste-
noses may indicate opportunities to improve patient se-
lection for coronary angiography, or to consider the
possibility of syndromes caused by abnormal coronary
vasoreactivity. Nevertheless, the exclusion of signiﬁcant
epicardial CAD with a high level of conﬁdence can be
important for high-quality diagnosis and patient man-
agement, and therefore the reported frequencies of
normal coronary ﬁndings should be understood within
this context (29,35–37).
4. TREATMENT
4.4 Guideline-Directed Medical Therapy
4.4.2 Additional Medical Therapy to Prevent MI and Death:
Recommendation
4.4.2.5 Additional Therapy to Reduce Risk of MI and Death
See Table 2 for the revised recommendation for chelation
therapy and Online Data Supplement 2 for evidence sup-
porting the recommendation.
4.4.2.5.4 Chelation Therapy
Chelation therapy, which consists of a series of intrave-
nous infusions of disodium ethylene diamine tetraacetic
acid (EDTA) in combination with other substances, has
been touted as a putative noninvasive means of
improving blood ﬂow in atherosclerotic vessels, treating
angina, and preventing cardiac events. EDTA combines
with polyvalent cations, such as calcium and cadmium
(a constituent of cigarette smoke that is associated with
cardiovascular risk) (43,44), to form soluble complexesTABLE 2 Recommendation for Chelation Therapy
2012 Recommendation 2014 Focused Upda
Class III: No Beneﬁt
1. Chelation therapy is not recommended with
the intent of improving symptoms or reducing
cardiovascular risk in patients with SIHD (38–41).
(Level of Evidence: C)
Class IIb
1. The usefulness of
is uncertain for re
events in patients
(Level of Evidence
SIHD indicates stable ischemic heart disease.that can be excreted. Advocates maintain that this process
can result in both regression of atherosclerotic plaques
and relief of angina and that EDTA reduces oxidative
stress in the vascular wall. Anecdotal reports have sug-
gested that EDTA chelation therapy can result in relief
of angina in patients with SIHD. Studies in patients
with intermittent claudication and SIHD have failed to
demonstrate improvements in exercise measures (38,39),
ankle-brachial index (38,39), or digital subtraction an-
giograms with chelation (40). A randomized controlled
trial (RCT) examining the effect of chelation therapy on
SIHD studied 84 patients with stable angina and a positive
treadmill test for ischemia (41). Those randomized to
active therapy received weight-adjusted disodium EDTA
chelation therapy for 3 hours per treatment, twice weekly
for 15 weeks, and then once monthly for an additional 3
months. There were no differences between groups in
changes in exercise time to ischemia, exercise capacity, or
quality-of-life scores. The National Center of Comple-
mentary and Alternative Medicine and the National Heart,
Lung, and Blood Institute conducted TACT (Trial to
Assess Chelation Therapy) (42), an RCT comparing che-
lation with placebo in patients who had experienced MI.
The primary composite endpoint of total mortality,
recurrent MI, stroke, coronary revascularization, or hos-
pitalization for angina occurred in 222 (26%) patients in
the chelation group and 261 (30%) patients in the placebo
group (hazard ratio: 0.82; 95% CI: 0.69 to 0.99; p¼0.035
[because of multiple comparisons, statistical signiﬁcance
was considered at p values #0.036]). No individual
endpoint differed signiﬁcantly between groups. Among
patients with diabetes mellitus, there was a 39% reduc-
tion (hazard ratio: 0.61; 95% CI: 0.45 to 0.83) in the
composite endpoint for the chelation-treated patients
relative to the placebo-treated patients (p¼0.02 for
interaction). Despite these positive ﬁndings, the TACT
investigators did not recommend the routine use of che-
lation therapy to reduce symptoms or cardiovascular
complications for all patients with SIHD, given the modest
overall beneﬁt, high proportion of patient withdrawals
(18% lost to follow-up), absence of adequate scientiﬁc
basis for the therapy, and possibility of a false positive
outcome. The large proportion of withdrawals was
especially concerning given that 50% more patients
withdrew from chelation therapy than from placebo,te Recommendation Comment
chelation therapy
ducing cardiovascular
with SIHD (38–42).
: B)
Modiﬁed recommendation (changed Class of
Recommendation from III: No Beneﬁt
to IIb and Level of Evidence from C to B).
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1937which raised important concerns about unmasking of
treatment assignments that could have inﬂuenced key
outcomes (e.g., revascularization or hospitalization for
angina). In addition, chelation therapy is not risk free.
Disodium EDTA, particularly when infused too rapidly,
may cause hypocalcemia, renal failure, and death (45,46).
Although disodium EDTA is approved by the U.S. Food and
Drug Administration for speciﬁc indications, such as iron
overload and lead poisoning, it is not approved for use in
preventing or treating cardiovascular disease. Accord-
ingly, the writing group ﬁnds that the usefulness of che-
lation therapy in cardiac disease is highly questionable.
4.4.4 Alternative Therapies for Relief of Symptoms in Patients
With Refractory Angina: Recommendation
See Table 3 for the recommendation on enhanced external
counterpulsation (EECP) and Online Data Supplement 3 for
evidence supporting the recommendation.
4.4.4.1 Enhanced External Counterpulsation
Although EECP was carefully reviewed in the 2012 SIHD
guideline (4), comments received after the guideline’s
publication prompted a re-examination of the existing
literature, even though no truly new data have become
available. EECP is a technique that uses inﬂatable cuffs
wrapped around the lower extremities to increase venous
return and augment diastolic blood pressure (47). The
cuffs are inﬂated sequentially from the calves to the thigh
muscles during diastole and are deﬂated instantaneously
during systole. The resultant diastolic augmentation in-
creases coronary perfusion pressure, and the systolic cuff
depression decreases peripheral resistance. Treatment is
associated with improved left ventricular diastolic ﬁlling,
peripheral ﬂow-mediated dilation, and endothelial func-
tion. Other putative mechanisms for improvement in
symptoms include recruitment of collaterals, attenuation
of oxidative stress and proinﬂammatory cytokines, pro-
motion of angiogenesis and vasculogenesis, and a pe-
ripheral training effect (48–51). EECP was approved by the
U.S. Food and Drug Administration in 1995 for the treat-
ment of patients with CAD and refractory angina pectoris
who fail to respond to standard revascularization pro-
cedures and aggressive pharmacotherapy. A treatment
course typically consists of 35 sessions of 1 hour each,
given 5 days a week. Contraindications include decom-
pensated heart failure, severe peripheral artery disease,
and severe aortic regurgitation.TABLE 3 Recommendation for EECP
2012 Recommendation 2014 F
Class IIb
1. EECP may be considered for relief of refractory angina
in patients with SIHD (47). (Level of Evidence: B)
Class IIb
1. EECP may b
in patients w
EECP indicates enhanced external counterpulsation, and SIHD, stable ischemic heart disease.The efﬁcacy of EECP in treating stable angina pectoris
has been evaluated in 2 RCTs and several observational
registry studies. In MUST-EECP (Multicenter Study of
Enhanced External Counterpulsation), 139 patients with
angina, documented CAD, and evidence of ischemia on
exercise testing were randomized to 35 hours of active
counterpulsation or to inactive counterpulsation (with
insufﬁcient pressure to alter blood pressure) (47). Time
to $1-mm ST-segment depression on stress testing
increased signiﬁcantly in patients treated with active
counterpulsation (from 33718 s to 37918 s) compared
with placebo (from 32621 s to 33020 s; p¼0.01). The
groups did not differ in terms of exercise duration,
change in daily nitroglycerin use, or mean frequency of
angina, although the percentage reduction in frequency
of anginal episodes was somewhat greater among patients
who received active counterpulsation. Of patients re-
ceiving EECP, 55% reported adverse events, including leg
and back pain and skin abrasions, compared with 26% in
the control group (relative risk: 2.13; 95% CI: 1.35 to 3.38),
with approximately half of these events categorized as
device related. An additional trial of EECP was conducted
in 42 symptomatic patients with CAD who were random-
ized (2:1 ratio) to 35 hours of either EECP (n¼28) or sham
EECP (n¼14) (51). Over the 7-week study period, average
Canadian Cardiovascular Society angina class improved
with EECP as compared with control (3.160.47 to
1.200.40 and 2.930.26 to 2.930.26 in EECP and sham
control, respectively; p<0.001). Data from RCTs on long-
term outcomes are lacking.
In a meta-analysis of 13 observational studies that
tracked 949 patients, Canadian Cardiovascular Society
anginal class was improved by $1 class in 86% of EECP-
treated patients (95% CI: 82% to 90%). There was,
however, a high degree of heterogeneity among the
studies, which lessens conﬁdence in the results of the
meta-analysis (Q statistic p¼0.008) (52). The EECP Con-
sortium reported results from 2,289 consecutive patients
undergoing EECP therapy at 84 participating centers,
including a subgroup of 175 patients from 7 centers who
underwent radionuclide perfusion stress tests before and
after therapy (53). Treatment was associated with
improved perfusion images and increased exercise dura-
tion. Similarly, the International EECP Registry reported
improvement of $1 Canadian Cardiovascular Society
angina class in 81% of patients immediately after the last
EECP treatment (54). Improvements in health-relatedocused Update Recommendation Comment
e considered for relief of refractory angina
ith SIHD (47). (Level of Evidence: B)
2012 recommendation
remains current.
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1938quality of life have also been reported with EECP, but there
is limited evidence with which to determine the duration
of the health-related beneﬁts of treatment (55,56).
In general, existing data, largely from uncontrolled
studies, suggest a beneﬁt from EECP among patients with
angina refractory to other therapy. Additional data from
well-designed RCTs are needed to better deﬁne the role of
this therapeutic strategy in patients with SIHD (57). On
the basis of this re-examination of the literature, the
recommendation about EECP remains unchanged from
the 2012 guideline.
5. CAD REVASCULARIZATION
5.2 Revascularization to Improve Survival: Recommendations
See Table 4 for recommendations on CAD revascularization
to improve survival and Online Data Supplement 4 for
evidence supporting the recommendations.
5.6 CABG Versus PCI
5.6.2 CABG Versus Drug-Eluting Stents
See Online Data Supplement 5 for additional evidence table.
Although the results of 10 observational studies
comparing CABG and drug-eluting stent (DES) implanta-
tion have been published (70–79), most of these studies
had short follow-up periods (12 to 24 months). In a meta-
analysis of 24,268 patients with multivessel CAD treated
with CABG or DES (80), the incidences of death and MI
were similar for the 2 procedures, but the frequency with
which repeat revascularization was performed was
roughly 4 times higher after DES implantation. Only 1
large RCT comparing CABG and DES implantation has
been published. The SYNTAX (Synergy Between Percuta-
neous Coronary Intervention With TAXUS and Cardiac
Surgery) trial randomly assigned 1,800 patients (of a total
of 4,337 who were screened) to receive DES or CABG
(66,81,82). Major adverse cardiac and cerebrovascular
events (MACCE)—a composite of death, stroke, MI,TABLE 4 Recommendations for CAD Revascularization to Impro
2012 Recommendation 2014 Focused Update
Class IIa
1. CABG is probably recommended in preference
to PCI to improve survival in patients with
multivessel CAD and diabetes mellitus,
particularly if a LIMA graft can be
anastomosed to the LAD artery (58–65).
(Level of Evidence: B)
Class I
1. A Heart Team approach
recommended in patien
mellitus and complex m
(Level of Evidence: C)
2. CABG is generally recom
preference to PCI to im
patients with diabetes m
multivessel CAD for whi
likely to improve surviv
complex 2-vessel CAD i
LAD), particularly if a L
anastomosed to the LA
the patient is a good ca
(58,61–65,59–69). (Lev
CABG indicates coronary artery bypass graft; CAD, coronary artery disease; LAD, left anterior d
and RCT, randomized controlled trial.or repeat revascularization during the 3 years after
randomization—occurred in 20.2% of patients who had
received CABG and 28.0% of those who had undergone
DES implantation (p<0.001). The rates of death and
stroke were not signiﬁcantly different; however, MI
(3.6% for CABG, 7.1% for DES) and repeat revasculariza-
tion (10.7% for CABG, 19.7% for DES) were more likely to
occur with DES implantation (82). At 5 years of follow-up
(83), MACCE occurred in 26.9% of patients who had
received CABG and 37.3% of those who had undergone
DES implantation (p<0.0001). The combined endpoint of
death, stroke, or MI was also lower in CABG-treated
patients than in DES-treated patients (16.7% versus
20.8%; p¼0.03) (83).
In SYNTAX, the extent of CAD was assessed using the
SYNTAX score, which is based on the location, severity,
and extent of coronary stenoses, with a low score indi-
cating less complicated anatomic CAD. In post hoc ana-
lyses, a low score was deﬁned as #22; intermediate, 23 to
32; and high, $33. The occurrence of MACCE correlated
with the SYNTAX score for DES patients but not for those
who had undergone CABG. At 12-month follow-up, the
primary endpoint was similar for CABG and DES in those
with a low SYNTAX score. In contrast, MACCE occurred
more often after DES implantation than after CABG in those
with an intermediate or high SYNTAX score (66). At 3 years
of follow-up, themortality rate was greater in subjects with
3-vessel CAD treated with DES than in those treated with
CABG (6.2% versus 2.9%). The differences in MACCE at 5-
year follow-up between those treated with DES or CABG
increased with an increasing SYNTAX score (83).
Although the utility of the SYNTAX score in everyday
clinical practice remains uncertain, it seems reasonable to
conclude from SYNTAX and other data that survival rates
of patients undergoing PCI or CABG with relatively un-
complicated and lesser degrees of CAD are comparable,
whereas for those with complex and diffuse CAD, CABG
appears to be preferable (81–83).ve Survival
Recommendations Comments
to revascularization is
ts with diabetes
ultivessel CAD (66).
mended in
prove survival in
ellitus and
ch revascularization is
al (3-vessel CAD or
nvolving the proximal
IMA graft can be
D artery, provided
ndidate for surgery
el of Evidence: B)
New recommendation
Modiﬁed recommendation (Class of
Recommendation changed from IIa to I,
wording modiﬁed, additional RCT added).
escending; LIMA, left internal mammary artery; PCI, percutaneous coronary intervention;
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19395.7.2 Studies Comparing PCI and CABG for Left Main CAD
See 2012 SIHD Guideline Data Supplement (Table 8-13) for
informational evidence tables (4).
Of all patients undergoing coronary angiography,
approximately 4% are found to have left main CAD (84),
>80% of whom also have signiﬁcant ($70% diameter)
stenoses in other epicardial coronary arteries. In pub-
lished cohort studies, it has been found that major clinical
outcomes 1 year after revascularization are similar with
PCI or CABG and that mortality rates are similar at 1, 2,
and 5 years of follow-up; however, the risk of undergoing
target-vessel revascularization is signiﬁcantly higher with
stenting than with CABG.
In the SYNTAX trial, 45% of screened patients with
unprotected left main CAD had complex disease that
prevented randomization; 89% of those underwent CABG
(66,81). In addition, 705 of the 1,800 patients with un-
protected left main CAD were randomized to either DES or
CABG. The majority of patients with left main CAD and a
low SYNTAX score had isolated left main CAD or left main
CAD plus 1-vessel CAD. The majority of those with an
intermediate score had left main CAD plus 2-vessel CAD,
and most of those with a high SYNTAX score had left main
CAD plus 3-vessel CAD. At 1 year, rates of all-cause death
and MACCE were similar among patients who had un-
dergone DES and those who had undergone CABG (81).
Repeat revascularization was performed more often in the
DES group than in the CABG group (11.8% versus 6.5%),
but stroke occurred more often in the CABG group (2.7%
versus 0.3%). At 3 years of follow-up, the incidence of
death in those undergoing left main CAD revasculariza-
tion with low or intermediate SYNTAX scores (<33) was
3.7% after DES and 9.1% after CABG (p¼0.03), whereas in
those with a high SYNTAX score ($33), the incidence of
death after 3 years was 13.4% after DES and 7.6% after
CABG (p¼0.10) (81). Because the primary endpoint of the
overall SYNTAX trial was not met (i.e., noninferiority
comparison of CABG and DES), the results of these sub-
group analyses need to be applied with caution. At
5 years of follow-up, MACCE rates did not differ signif-
icantly between groups of patients with low or inter-
mediate SYNTAX scores, but signiﬁcantly more patients
in the DES group with high SYNTAX scores had
MACCE than in the CABG group (46.5% versus 29.7%;
p¼0.003) (86).
In the LE MANS (Study of Unprotected Left Main
Stenting Versus Bypass Surgery) trial (87), 105 patients
with left main CAD were randomized to receive PCI or
CABG. Although a low proportion of patients treated with
PCI received DES (35%) and a low proportion of patients
treated with CABG received internal mammary grafts
(72%), the outcomes at 30 days and 1 year were similar
between the groups. In the PRECOMBAT (Premier of
Randomized Comparison of Bypass Surgery VersusAngioplasty Using Sirolimus-Eluting Stent in Patients
With Left Main Coronary Artery Disease) trial of 600 pa-
tients with left main disease, the composite endpoint of
death, MI, or stroke at 2 years occurred in 4.4% of patients
treated with DES and 4.7% of patients treated with CABG,
but ischemia-driven target-vessel revascularization was
required more often in the patients treated with PCI (9.0%
versus 4.2%) (88).
The results from these 3 RCTs suggest (but do not
deﬁnitively prove) that major clinical outcomes in
selected patients with left main CAD are similar with
CABG and PCI at 1- to 2-year follow-up but that repeat
revascularization rates are higher after PCI than after
CABG. RCTs with extended follow-up of $5 years are
required to provide deﬁnitive conclusions about the
optimal treatment of left main CAD; 2 such studies are
under way. In a meta-analysis of 8 cohort studies and 2
RCTs (89), death, MI, and stroke occurred with similar
frequency in the PCI- and CABG-treated patients at 1, 2,
and 3 years of follow-up. Target-vessel revasculariza-
tion was performed more often in the PCI group at
1 year (OR: 4.36), 2 years (OR: 4.20), and 3 years (OR:
3.30).
Additional analyses using Bayesian methods, initiated
by the Task Force, have afﬁrmed the equivalence of PCI
and CABG for improving survival in patients with unpro-
tected left main CAD who are candidates for either
strategy (12). A Bayesian cross-design and network meta-
analysis was applied to 12 studies (4 RCTs and 8 obser-
vational studies) comparing CABG with PCI (n¼4,574
patients) and to 7 studies (2 RCTs and 5 observational
studies) comparing CABG with medical therapy (n¼3,224
patients). The ORs of death at 1 year after PCI compared
with CABG did not differ among RCTs (OR: 0.99; 95%
Bayesian credible interval 0.67 to 1.43), matched cohort
studies (OR: 1.10; 95% Bayesian credible interval 0.76 to
1.73), and other types of cohort studies (OR: 0.93; 95%
Bayesian credible interval 0.58 to 1.35). A network meta-
analysis suggested that medical therapy is associated
with higher risk of death at 1 year than is the use of PCI for
patients with unprotected left main CAD (OR: 3.22; 95%
Bayesian credible interval 1.96 to 5.30) (12). In that study,
the Bayesian method generated a credible interval that
has a high probability of containing the true OR. In other
words, the true value for the OR has a 95% probability
of lying within the interval of 0.68 to 1.45. Because the
value 1 is included in the credible interval, which is
also symmetrical, the results show no evidence of a dif-
ference between PCI and CABG for 1-year mortality
rate. The possibility that PCI is associated with increased
or decreased 1-year mortality over CABG is small (<2.5%
for a possible 45% increase or for a 32% decrease, ac-
cording to the deﬁnition of the 95% Bayesian credible
interval).
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In addition to patients’ coronary anatomy, left ventricular
function, and history of prior revascularization, clinical
features such as the existence of coexisting chronic con-
ditions might inﬂuence decision making. However, the
paucity of information about special subgroups is one of
the greatest challenges in developing evidence-based
guidelines applicable to large populations. As is the case
for many chronic conditions, studies speciﬁcally geared
toward answering clinical questions about the manage-
ment of SIHD in women, older adults, and persons with
chronic kidney disease are lacking. The “ACCF/AHA
guidelines for the management of patients with unstable
angina/non–ST-elevation myocardial infarction” (90,91)
address special subgroups. The present section echoes
those management recommendations. Although this sec-
tion will brieﬂy review some special considerations for
diagnosis and therapy in certain groups of patients, the
general approach should be to apply the recommenda-
tions in this guideline consistently among groups.
5.12.3 Diabetes Mellitus
See Online Data Supplement 6 for additional evidence table.
In the FREEDOM (Future Revascularization Evaluation in
Patients With Diabetes Mellitus: Optimal Management of
Multivessel Disease) trial, 1,900 patients with multivessel
CAD were randomized to either PCI with DES or CABG (68).
The primary outcome—a composite of death, nonfatal MI,
or nonfatal stroke—occurred less frequently in the CABG
group (p¼0.005), with 5-year rates of 18.7% in the CABG
group and 26.6% in the DES group. The beneﬁt of CABG
was related to differences in rates of both MI (p<0.001)
and death from any cause (p¼0.049). Stroke was more
frequent in the CABG group, with 5-year rates of 5.2% in
the CABG group and 2.4% in the DES group (p¼0.03).
Other studies have provided mixed evidence, but none
has suggested a survival advantage of PCI. The 5-year
update from the SYNTAX trial did not show a signiﬁcant
advantage in survival after CABG compared with survival
after DES in patients with diabetes mellitus and multi-
vessel CAD (12.9% versus 19.5%; p¼0.065) (83). A meta-
analysis of 4 trials showed no signiﬁcant advantage
in survival after CABG compared with survival after
PCI for patients with diabetes mellitus (7.9% versus
12.4%; p¼0.09) (92). In a pooled analysis, it was
found that patients with diabetes mellitus assigned to
CABG had improved survival (23% versus 29%; p¼0.008
for the interaction between presence of diabetes
mellitus and type of revascularization procedure after
adjustment) (93).
The strongest evidence supporting the use of CABG
over PCI for patients with diabetes mellitus and multi-
vessel CAD comes from a published meta-analysis of 8trials (including FREEDOM) (68). The study of 3,131 pa-
tients showed that at 5-year or longest follow-up, patients
with diabetes mellitus randomized to CABG had a lower
all-cause mortality rate than did those randomized to PCI
with either DES or bare metal stent (relative risk 0.67; 95%
CI: 0.52 to 0.86; p¼0.002) (94).
In summary, patients with SIHD and diabetes mellitus
should receive GDMT. For patients whose symptoms
compromise their quality of life, revascularization should
be considered. CABG appears to be associated with lower
risk of mortality than is PCI in most patients with diabetes
mellitus and complex multivessel disease, although the
Heart Team may identify exceptions. To address the
important issue of deciding between PCI and CABG in
patients with diabetes mellitus and complex multivessel
CAD, a Heart Team approach would be beneﬁcial. This
was an integral component of the FREEDOM, SYNTAX,
and BARI trials (68,66,59) and is therefore emphasized in
this setting. The Heart Team is a multidisciplinary team
composed of an interventional cardiologist and a cardiac
surgeon who jointly 1) review the patient’s medical con-
dition and coronary anatomy, 2) determine that PCI and/
or CABG are technically feasible and reasonable, and,
3) discusses revascularization options with the patient
before a treatment strategy is selected.
Future research may be facilitated by including a ﬁeld
in the National Cardiovascular Data PCI Registry and the
STS database to identify cases “turned down” for the
alternative revascularization strategy.PRESIDENTS AND STAFF
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